Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jan 31;26:3. doi: 10.1186/s40824-022-00249-7

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 5 — Comparative efficacy study of the NC versus free drug combination (FDC) regimens in a preclinical human lung cancer mouse model. (A) Experimental schedule elucidating the establishment of the A549^cisR xenograft model and drug administration. (B) The change in tumor volume was recorded using a Vernier caliper. Mice were treated with various drug combinations. (C) The tumor inhibition rate of each treatment is presented. (D) Variances in the bodyweight of each grouped mouse were measured after the treatment. (E-G) Histological assessment was used to evaluate the therapeutic effects. The excised tumors were harvested and histologically analyzed. Scale bars, 50 μm. (H and I) The quantification of TUNEL-positive (H) and Ki-67-positive (I) cells in each group is shown in the histogram